Skip to Content

Giapreza Approval History

Giapreza (angiotensin II) is a synthetic human angiotensin II vasoconstrictor indicated for the treatment of hypotension in adults with septic or other distributive shock.

Development History and FDA Approval Process for Giapreza

DateArticle
Dec 21, 2017Approval FDA Approves Giapreza (angiotensin II) to Treat Dangerously Low Blood Pressure
Aug 28, 2017La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-501
May 21, 2017Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide